• Tempus AI recently announced a collaboration with Median Technologies to integrate Median’s FDA-cleared eyonis® LCS lung cancer screening software into the Tempus Pixel platform, enhancing AI-enabled analysis of CT images for lung nodule detection and risk stratification.
• This integration broadens Tempus AI’s radiology footprint by adding non-invasive malignancy scoring at the point of nodule detection, potentially making its precision medicine ecosystem more useful for clinicians running lung cancer screening programs.
• We’ll now examine how adding FDA-cleared eyonis LCS to Tempus Pixel could influence the company’s AI diagnostics-focused investment narrative.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Tempus AI Investment Narrative Recap

To own Tempus AI, you have to believe its precision medicine and AI diagnostics platform can scale across oncology and imaging while eventually narrowing persistent losses. The Median Technologies collaboration strengthens the lung cancer screening story but does not clearly change the most immediate catalyst, which is progress toward improving profitability, nor the key risk that heavy AI and infrastructure spending continues to outpace revenue.

Among recent updates, the launch of Paige Predict in January 2026 looks especially relevant, as it extends Tempus’s AI-driven diagnostics into digital pathology across 16 cancer types. Together with the eyonis LCS integration in radiology, it reinforces the central catalyst that Tempus can deepen adoption of its multimodal platform across both imaging and genomics, even as reimbursement and monetization of AI-only tools remain uncertain.

However, investors should also be aware that growing AI capabilities do not eliminate the risk that reimbursement and regulatory friction could still...

Tempus AI's narrative projects $2.1 billion revenue and $295.0 million earnings by 2028. This requires 29.7% yearly revenue growth and a $494.7 million earnings increase from -$199.7 million today.

Uncover how Tempus AI's forecasts yield a $87.92 fair value, a 69% upside to its current price.

Exploring Other Perspectives

Twenty five fair value estimates from the Simply Wall St Community range from US$25.77 to US$187.81, underscoring how far apart individual views on Tempus AI can be. You should weigh those opinions against the central risk that mounting R&D and AI infrastructure spend may continue to delay any path toward durable cash flow generation and what that could mean for future execution.

Explore 25 other fair value estimates on Tempus AI - why the stock might be worth less than half the current price!

Build Your Own Tempus AI Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tempus AI research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 28 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• Find 53 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.